特拉华州威尔明顿的。，Feb. 1, 2021 /PRNewswire/ -- DuPont (NYSE: DD) announced today the preliminary results of its exchange offer in connection with the previously announced separation of its nutrition and biosciences business (the "N&B Business") and merger of Nutrition & Biosciences, Inc. ("N&B"), a DuPont subsidiary formed to hold the N&B Business, with a subsidiary of International Flavors & Fragrances Inc. ("IFF") (NYSE: IFF). DuPont intends to accept, subject to proration, shares of DuPont common stock validly tendered in the exchange offer.
此次换股要约的最终换股比例为0.7180股N&B普通股换一股杜邦普通股(有效投标且未适当撤回并接受交换)。在完成N&B与IFF子公司的合并后，每一股N&B普通股将转换为一股IFF普通股。因此，在交换要约中投标杜邦普通股的杜邦股东，每接受交换的一股杜邦普通股，将获得约0.7180股IFF普通股(以现金代替零点股为准)。
交换计划初步结果
根据交易所提供,到期后一分钟12点,纽约,2021年1月29日,根据交易所提供的初步计算代理,总共大约369165753股的杜邦公司普通股是招标,而不是正确交换期满前撤回报价,包括大约80,609,346股按照保证交付程序投标。
根据交换要约条款的初步结果，杜邦将在交换要约中以总计约197,410,113股杜邦普通股交换杜邦持有的141,740,461股N&B普通股。
根据报告的杜邦普通股在交换要约到期前未适当撤回的总数量，包括根据担保交付程序投标的股票，交换要约被超额认购约171,755,640股，初步比例系数约为52.4563%。初步结果包括由奇数批股东(符合奇数批待遇的股东不受比例限制)投标的约7907187股杜邦普通股。由于超过197,410,113股的杜邦普通股被投标，杜邦将在此次交易中分发所有的N&B普通股。因此，不会出现清理的副产品。
杜邦公司will not be able to determine the final proration factor until after the full expiration of the exchange offer's guaranteed delivery period at 5:00 p.m., New York City time, on February 2, 2021. DuPont will publicly announce the final results, including the final proration factor, which may be different from today's preliminary results and preliminary estimate of the proration factor, after they have been determined. Once the final results of the exchange offer are available, and the calculation of the number of shares of N&B common stock received by each stockholder in the exchange offer is determined, IFF's transfer agent will deliver the appropriate number of shares of IFF common stock, as well as cash in lieu of fractional shares.
欲了解更多有关交换优惠的信息，请访问www.dupontexchangeoffer.com或者联系信息代理乔治森有限责任公司，电话888-660-8331。
杜邦™，杜邦椭圆标志，以及以™表示的所有商标和服务标志，SM或者®除非另有说明，均为杜邦德内莫尔公司附属公司所有。
2/1/21
对杜邦公司
杜邦公司(NYSE: DD)是全球创新领导者，以科技为基础的材料、配料和解决方案帮助改变工业和日常生活。我们的员工运用不同的科学和专业知识，帮助客户在电子、交通、建筑、水、健康和保健、食品和工人安全等关键市场推进他们的最佳理念，并提供必要的创新。有关该公司、其业务和解决方案的更多信息，请访问www.ljlcyg.com．投资者可访问网站投资者关系部分的信息，网址为investors.dupont.com．
关于杜邦营养与生物科学
杜邦营养与生物科学应用专家科学，为食品、饮料、膳食补充剂和制药行业提供以市场为导向、健康和可持续的解决方案。我们还在一系列市场中使用尖端生物技术，以推进基于生物的解决方案，以满足不断增长的人口的需求，同时为子孙后代保护我们的环境。我们是创新的解决者，帮助我们的客户将挑战转化为高价值的商业机会。更多信息:www.dupontnutritionandhealth.com或者www.biosciences.dupont.com．
关于前瞻性陈述的注意事项
该沟通在联邦证券法的含义中包含“前瞻性陈述”，包括“证券法”第27A条，以及1934年“修订”的“证券交流法”第21E条（“交流法”）。在这方面，前瞻性陈述往往地满足预期的未来业务和财务绩效和财务状况，通常包含“期待”等词语“预期”，“打算”，“计划，”“求，”“求，”“请参阅，”“遗嘱，”，“目标，”类似的表情，以及这些词的变化或否定。他们的自然地址的前瞻性陈述，对不同程度，不确定的事项，如关于交易的陈述，交易的好处和协同作用，联合公司和产品的未来机会，拟议的组织和运营的好处合并公司的型号和关于杜邦，IFF和N＆B的未来行动，财务或经营业绩，资本配置，股息政策，债务率，预期的业务水平，未来盈利，计划活动，预期增长，市场机会，策略，金融或经营业绩，资本配置，资本分配，竞争以及未来时期的其他期望和目标。有几个因素可能导致实际计划和结果与前瞻性陈述中表达或暗示的那些不同。这些因素包括但不限于（1）缔约方能够满足关于交易的会计和税收处理的预期，（2）相关税和其他法律的变化，（3）可能是不可预见的负债，未来的资本支出，收入，费用，盈利，协同作用，经济绩效，债务，财务状况，损失，可能影响交易价值的未来前景，业务和管理战略，（4）与Corteva分配有关的风险和费用2019年6月1日（“Corteva Distribution”）和Dow Inc.的分销2019年4月1日（“Dow分布”和Corteva分配“以前的分布”），包括某些遗留负债的赔偿 of E. I. du Pont de Nemours and Company ("Historical EID"), a subsidiary of Corteva, in connection with the Corteva Distribution and potential liability arising from fraudulent conveyance and similar laws in connection with the Previous Distributions, (5) risks and costs related to the performance under and impact of the cost sharing arrangement by and between DuPont, Corteva, Inc. and The Chemours Company related to future eligible PFAS liabilities, (6) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses, (7) uncertainty as to the long-term value of DuPont common stock, (8) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade, (9) inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with the accounting principles generally accepted in the United States of America and related standards, or on an adjusted basis, (10) the integration of IFF and its Frutarom business and/or N&B being more difficult, time consuming or costly than expected, (11) the failure to achieve expected or targeted future financial and operating performance and results, (12) the possibility that IFF may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the transaction within the expected time frames or at all or to successfully integrate Frutarom and N&B, (13) customer loss and business disruption being greater than expected following the transaction, (14) legislative, regulatory and economic developments; (15) an increase or decrease in the anticipated transaction taxes (including due to any changes to tax legislation and its impact on tax rates (and the timing of the effectiveness of any such changes)), (16) potential litigation relating to the transaction that could be instituted against DuPont, IFF or their respective directors, (17) risks associated with third party contracts containing consent and/or other provisions that may be triggered by the transaction, (18) negative effects of the consummation of the transaction on the market price of DuPont's and/or IFF's common stock, (19) risks relating to the value of the IFF shares to be issued in the transaction and uncertainty as to the long-term value of IFF's common stock, (20) the impact of the failure to comply with U.S. or foreign anti-corruption and anti-bribery laws and regulations, (21) the ability of N&B or IFF to retain and hire key personnel, (26) the risk that N&B and IFF will incur significant indebtedness in connection with the transaction, and the degree to which IFF will be leveraged following completion of the transaction may materially and adversely affect its business, financial condition and results of operations, (23) that N&B may not achieve certain targeted cost and productivity improvements, which could adversely impact its results of operations and financial condition, and (24) other risks to DuPont's, N&B's and IFF's business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost of energy and raw materials; business or supply disruption, including in connection with the Previous Distributions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns, disasters, public health issues, epidemics and pandemics, including COVID-19, or the fear of such events, and the inherent unpredictability, duration and severity of such events, which could result in a significant operational event for DuPont, N&B or IFF, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's, N&B's or IFF's intellectual property rights;, as well as management's response to any of the aforementioned factors. These risks, as well as other risks associated with the merger, are more fully discussed in the registration statement and proxy statement filed by IFF and the registration statement filed by N&B. While the list of factors presented here is, and the list of factors presented in registration statements filed by each of IFF and N&B in connection with the transaction, are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Further lists and descriptions of risks and uncertainties can be found in IFF's annual report on Form 10-K for the year ended December 31, 2019, DuPont's annual report on Form 10-K for the year ended December 31, 2019, and each of IFF's and DuPont's respective subsequent reports on Form 10-Q, Form 10-K and Form 8-K, the contents of which are not incorporated by reference into, nor do they form part of, this announcement. Any other risks associated with the transaction are more fully discussed in the registration statements filed with the SEC. While the list of factors presented here is, and the list of factors presented in the registration statements, as amended, filed by each of IFF or N&B are representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on IFF's, DuPont's or N&B's consolidated financial condition, results of operations, credit rating or liquidity. None of IFF, DuPont nor N&B assumes any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
关于交易的附加信息和在哪里找到它
这种通信并不打算,不得构成要约出售或要约出售或征集的征集收购任何证券或征集投票批准,不得有任何出售证券的任何管辖权的报价,根据任何该等司法管辖区的证券法，在注册或取得资格之前进行招揽或出售均属非法。除非通过符合《1933年证券法》(经修订的《证券法》)第10节要求的招股书，否则不得发行证券。就该交易而言，N&B已在2020年12月31日的S-4/S-1表格上提交了一份包含招股说明书的注册声明，IFF已在2020年12月31日的S-4表格上提交了一份包含招股说明书的注册声明(合称为“注册声明”)。杜邦公司已向美国证券交易委员会提交了一份附表。投资者和证券持有人应阅读注册声明，杜邦的时间表和这些文件的任何修订或补充，以及任何其他相关文件提交或提交给美国证券交易委员会，因为它们将包含n&b, iff和杜邦和交易的重要信息。注册声明、杜邦的时间表和其他与该交易相关的文件(当它们可用时)也可以从美国证券交易委员会的网站免费获得www.sec.gov．这些文件和每个公司的其他文件与SEC(可用时)也可以免费获得,杜邦和n和b,在书面请求我国LLC在美洲的1290大道,9号楼,纽约,纽约10104,或通过电话888-660-8331,或者,敌我识别,请向纽约10019 West 57 Street 521号的International flavor & Fragrances Inc.投资者关系部提出书面请求或致电(212)708-7164。
此外，对于任何有关交换要约的问题，一般您可以联系信息代理Georgeson LLC，电话888-660-8331。
查看原创内容下载多媒体:http://www.prnewswire.com/news-releases/dupont-announces-preliminary-results-of-exchange-offer-in-connection-with-iff-transaction-301218563.html
源杜邦